Yohei Hashimoto MD, PhD, Hayato Yamana MD, PhD, Masao Iwagami MD, PhD, Sachiko Ono MPH, PhD, Yoshinori Takeuchi DVM, PhD, Nobuaki Michihata MD, PhD, Kohei Uemura PhD, Hideo Yasunaga MD, PhD, Makoto Aihara MD, PhD 及 Toshikatsu Kaburaki MD, PhD
Ophthalmology, 2023-03-01, 卷 130, 期 3, 頁面 256-264, Copyright © 2022 American Academy of Ophthalmology

英文摘要

This study aimed to investigate the risk of ocular adverse events following COVID-19 mRNA vaccine administration. Researchers employed two study designs: matched cohort and self-controlled case series (SCCS) studies. Individuals who received the COVID-19 vaccine (BNT162b2) from February 2021 to September 2021 were included. The study analyzed individuals who developed ocular adverse events. The findings revealed no significant increase in the risk of uveitis, scleritis, retinal vein occlusion (RVO), or optic neuritis after vaccination.

However, there were some limitations, such as the inability to obtain detailed information about the eyes and potential unmeasured confounders in the matched cohort study. Despite these limitations, this research provides important insights into the association between COVID-19 vaccines and ocular adverse events.

中文摘要

本研究旨在調查2019冠狀病毒病(COVID-19) mRNA疫苗接種後眼科不良反應的風險。研究人員使用了兩種研究設計：配對隊列Matched cohort研究和自控病例序列self-controlled case series研究。從2021年2月至2021年9月接種COVID-19疫苗(BNT162b2)的個體被納入研究。研究人員分析了發生眼科不良反應的個體。研究發現疫苗接種後，葡萄膜炎、鞏膜炎、視網膜靜脈阻塞(RVO)和視神經炎的風險並無顯著增加。

然而，研究存在一些限制，如無法獲得眼睛的詳細信息，配對隊列研究中可能存在未測量的混淆因素等。儘管如此，這項研究為了解COVID-19疫苗與眼科不良事件之間的關聯提供了重要信息。